Latest news with #FreseniusMedicalCare
Yahoo
10-07-2025
- Business
- Yahoo
When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Let's talk about the popular Fresenius Medical Care AG (ETR:FME). The company's shares saw a double-digit share price rise of over 10% in the past couple of months on the XTRA. While good news for shareholders, the company has traded much higher in the past year. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Let's examine Fresenius Medical Care's valuation and outlook in more detail to determine if there's still a bargain opportunity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The share price seems sensible at the moment according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 22.24x is currently trading slightly above its industry peers' ratio of 22.13x, which means if you buy Fresenius Medical Care today, you'd be paying a relatively sensible price for it. And if you believe Fresenius Medical Care should be trading in this range, then there isn't really any room for the share price grow beyond the levels of other industry peers over the long-term. Furthermore, Fresenius Medical Care's share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. This may mean it is less likely for the stock to fall lower from natural market volatility, which suggests less opportunities to buy moving forward. View our latest analysis for Fresenius Medical Care Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Fresenius Medical Care's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value. Are you a shareholder? FME's optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at FME? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio? Are you a potential investor? If you've been keeping an eye on FME, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the positive outlook is encouraging for FME, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Diving deeper into the forecasts for Fresenius Medical Care mentioned earlier will help you understand how analysts view the stock going forward. Luckily, you can check out what analysts are forecasting by clicking here. If you are no longer interested in Fresenius Medical Care, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-07-2025
- Business
- Yahoo
Zacks.com featured highlights Fresenius Medical Care, Eldorado Gold, Hope Bancorp and Heritage Insurance
Chicago, IL – July 8, 2025 – The stocks in this week's article are Fresenius Medical Care AG & Co. FMS, Eldorado Gold EGO, Hope Bancorp Inc. HOPE and Heritage Insurance Holdings, Inc. HRTG. The U.S. stock market bounced back from its April lows, ending the first half of the year on a strong note. Fears over the impact of tariffs somewhat eased, and a strong June jobs report helped ease concerns about an economic slowdown. But despite the rebound, there's still an air of caution. Trade tensions remain unresolved, with the risk of additional tariffs on the table. Meanwhile, the Federal Reserve's next move on interest rates remains uncertain, despite growing pressure from U.S. President Trump. In a market clouded by unpredictability, value investing is a sensible strategy. These are stocks of companies that may be undervalued but have strong fundamentals. They tend to offer stability when markets get shaky, with the potential for long-term gains. Rather than chasing fast-moving, hype-driven stocks, putting your money into solid businesses trading at fair or discounted prices could be the smarter move now. Fresenius Medical Care AG & Co., Eldorado Gold, Hope Bancorp Inc. and Heritage Insurance Holdings, Inc. are some value stocks with high earnings yield that investors can consider betting on. Earnings yield, expressed in percentage, is calculated as (Annual Earnings per Share/Market Price) x 100. This metric measures the anticipated yield (or return) from earnings for each dollar invested in a stock today. While comparing stocks, if other factors are similar, investors can look for the one with a higher earnings yield. Firms with higher earnings yield are considered underpriced, while those with lower earnings yield are seen as overpriced. Importantly, earnings yield can also be used to compare the performance of a market index with the 10-year Treasury yield to get a sense of the return on investment it offers compared to virtually risk-free returns. When the yield of the market index is more than the 10-year Treasury yield, stocks can be considered as undervalued than bonds. In this situation, investing in the stock market would be a better option for a value investor. Fresenius Medical Care is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. The Zacks Consensus Estimate for FMS' 2025 and 2026 earnings implies year-over-year growth of 33% and 12%, respectively. Estimates for 2025 and 2026 earnings per share have moved up by 6 cents and 13 cents, respectively, over the past 30 days. Fresenius Medical Care currently sports a Zacks Rank #1 and has a Value Score of B. Eldorado Gold is a gold producer with mining, development and exploration operations in Turkey, Canada and Greece. The Zacks Consensus Estimate for EGO's 2025 and 2026 earnings implies year-over-year growth of 10% and 55%, respectively. Estimates for 2025 and 2026 earnings per share have moved up by 9 cents and 16 cents, respectively, over the past 30 days. Eldorado Gold currently sports a Zacks Rank #1 and has a Value Score of A. Hope Bancorp operates as a bank holding company, providing commercial banking services primarily to small- to medium-sized businesses and individuals in the United States. The Zacks Consensus Estimate for HOPE's 2025 and 2026 earnings implies year-over-year growth of 12% and 40%, respectively. Estimates for 2025 and 2026 earnings per share have moved up by 4 cents and 8 cents, respectively, over the past 30 days. Hope Bancorp currently sports a Zacks Rank #1 and has a Value Score of B. Heritage Insurance provides personal and commercial residential insurance products. The Zacks Consensus Estimate for HRTG's 2025 and 2026 earnings implies year-over-year growth of 62% and 13%, respectively. EPS estimates for the current and next year have moved up by 82 cents and 55 cents, respectively, over the past 60 days. Heritage Insurance currently sports a Zacks Rank #1 and has a Value Score of B. You can get the rest of the stocks on this list by signing up now for a 2-week free trial to the Research Wizard stock picking and backtesting software. You can also create your own strategies and test them first before making investments. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit at: Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Heritage Insurance Holdings, Inc. (HRTG) : Free Stock Analysis Report Eldorado Gold Corporation (EGO) : Free Stock Analysis Report Hope Bancorp, Inc. (HOPE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
03-07-2025
- Health
- Yahoo
Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico
High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany, July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration (HighVolumeHDF) access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to develop a pilot program that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies. Fresenius Medical Care Mexico and CCINSHAE signed a two-year contract to enable the installation of the Fresenius Medical Care 5008S CorDiax technology in participating renal treatment centers in CCINCSHAE Centers in Mexico City (CDMX) and its metropolitan area, for a total of 150 systems in all. "The groundbreaking pilot program, with its mission to provide chronic kidney disease patients with access to high quality treatments that were previously out of their reach, represents an important advancement in CKD in Mexico," said Edgar Robles, Fresenius Medical Care Mexico's Managing Director of Care Enablement Commercial Operations. This technology provides standard hemodialysis as well as HighVolumeHDF, a therapy that has demonstrated improved patient well-being while increasing cost-effectiveness in most health care systems. The initiative between Fresenius Medical Care and the CCINSHAE has recently provided HighVolumeHDF treatment to 240 new CCINSHAE patients who do not have public or private medical coverage. Further 410 regular patients, who are covered by public or private medical insurance, already started receiving HighVolumeHDF last year. Some of these patients were part of the hemodialysis (HD) program in CCINSHAE centers and transitioned to HighVolumeHDF, while others were new patients assigned to CCINSHAE centers for various reasons, including new diagnoses, transitions from peritoneal dialysis to hemodiafiltration or patients entering the transplant program, thus doubling the number of patients via these other sources. "Fresenius Medical Care is committed to providing access to innovative therapies such as HighVolumeHDF," continued Robles. "Our approach is to raise quality standards in dialysis, which also improves the quality of life of patients, and simplifies operational procedures and provides efficient hemodialysis solutions for healthcare professionals." High-Volume Hemodiafiltration is backed by multiple clinical studies, including the international, randomized and controlled CONVINCE1 Trial, which compares high-volume hemodiafiltration with standard high-flux hemodialysis. The study reported a 23% reduction rate on average of all-cause mortality for patients treated with High-Volume Hemodiafiltration compared to those treated with the more commonly used high-flux hemodialysis. In the Americas, Fresenius Medical Care's HighVolumeHDF therapy is currently used in Argentina, Brazil, Canada, Caribbean Islands, Chile, Colombia, Ecuador, Mexico, Panama, Peru, and Uruguay. In the future, the company wants to bring HighVolumeHDF therapy – already widely used in Europe, Latin America, and Asia Pacific – for people living with kidney diseases in the U.S. In February 2024, Fresenius Medical Care announced it was the first company to receive U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System. In May 2025, the company received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broader commercialization efforts across the U.S. later this year, followed by a full-scale commercial launch in 2026. Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) is part of the Public Healthcare system in Mexico (Comisión Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta Especialidad). About Fresenius Medical Care:Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the company's website at The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803). Disclaimer:This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release. 1Blankestijn PJ et al., CONVINCE Scientific Committee Investigators, Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure, N Engl J Med 2023 Aug 24;389(8):700-709 Media contactEmanuela CariolagianT +1 213 706 0051 Christine PetersT +49 160 60 66 Contact for analysts and investorsDr. Dominik HegerT +49 6172 609 View original content to download multimedia: SOURCE Fresenius Medical Care Holdings, Inc. Sign in to access your portfolio
Yahoo
25-06-2025
- Business
- Yahoo
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
Fresenius Medical Care FMS recently unveiled its forward-looking 'FME Reignite' strategy at the 2025 Capital Markets Day, aiming to achieve industry-leading profitability while optimizing capital structure and advancing innovation in renal care. This comprehensive plan builds on the momentum of its prior transformation initiatives and integrates a sharp focus on capital returns, technological leadership and organizational agility. At the heart of the FME Reignite strategy lies an aggressive expansion of the existing FME25 program, now rebranded as FME25+, targeting €1.05 billion in sustainable cost savings by 2027. This €300 million increase over prior goals reflects the company's focus on operational excellence and margin expansion. These savings are expected to be channeled directly into margin improvement, helping FMS achieve its mid-teens operating income margin target by 2030 across both its Care Delivery and Care Enablement segments. By establishing Value-Based Care ('VBC') as a standalone segment, Fresenius enhances transparency and strategic clarity. Having generated €1.8 billion in 2024 revenues, this business unit is built around long-term partnerships with both public and private payors in the United States, aiming to deliver better outcomes at lower costs. The VBC model aligns well with broader healthcare trends favoring preventive, personalized care and is expected to become a material contributor to Fresenius' growth and resilience. FME25+ not only supports profitability but also enhances scalability, standardization, and efficiency across clinics and manufacturing sites. As a vertically integrated player, Fresenius is well-positioned to leverage synergies across its operating arms to streamline service delivery while maintaining care quality. Image Source: Fresenius Medical Care A key pillar of the strategy is a new capital allocation framework designed to balance reinvestment and shareholder returns. Fresenius plans to allocate €800 million to €1 billion annually for capital expenditures through 2030, reinforcing its innovation pipeline and core operations. Simultaneously, it aims to reduce its net financial leverage to a more conservative 2.5X-3.0X range, down from the earlier 3.0X-3.5X target, demonstrating a prudent approach amid macroeconomic uncertainties. To return value to shareholders, Fresenius will initiate a €1 billion share buyback program over two years beginning in 2025 and has committed to a dividend payout ratio of 30-40%. This dual-pronged return strategy underscores a clear intent to enhance investor confidence while maintaining financial flexibility. Image Source: Fresenius Medical Care Another cornerstone of the strategy is the upcoming U.S. commercial launch of the 5008X CAREsystem, Fresenius's next-generation dialysis machine. The FDA-cleared 5008X enables high-volume hemodiafiltration (HVHDF), a modality that has demonstrated significant survival and quality-of-life benefits compared to conventional hemodialysis. Backed by the CONVINCE study, HVHDF showed a 4.4% mortality reduction over 2.5 years and promises lower hospitalization and improved treatment consistency. Fresenius plans to replace all 2008T machines in its U.S. clinics with the 5008X by 2030, driving not only clinical outcomes but also operational efficiencies such as reduced clinic labor and drug use. With its market-leading installed base and exclusive FDA clearance, the company also expects to expand its market share in disposables tied to this platform. Through FME Reignite, Fresenius Medical Care is repositioning itself as a financially disciplined, innovation-driven, and patient-centered leader in renal care. By combining cost control with growth investments, optimizing capital allocation, and advancing clinical standards, the company is set to unlock meaningful long-term value for patients and shareholders alike. Baxter International BAX, DaVita Inc. DVA and Outset Medical OM are also navigating profitability and capital strategies through distinct lenses shaped by their business models and market positions. Baxter, having divested its kidney care business, is now focused on rebuilding profitability across its hospital and digital health portfolios. The company has improved gross margins through cost controls and is deleveraging its balance sheet following recent spin-offs. Capital allocation remains disciplined,with a renewed focus on organic investments and debt reduction. In contrast, DaVita, a pure-play dialysis provider, maintains stable operating margins through scale efficiencies and disciplined cost management. DVA's profit sharing strategy depends heavily on share buybacks. The company recently issued senior notes worth $1 billion, reflecting a high-leverage model focused on returning capital to shareholders. Meanwhile, Outset Medical, a younger player, is prioritizing margin improvement and cash burn reduction. While still unprofitable, OM has improved gross margins to ~37% and is narrowing its losses through cost discipline and operational streamlining. However, Outset Medical remains reliant on external funding, often through dilutive equity raises. Shares of FMS have outperformed its industry as well as its peers. The company's shares have risen 19.8% year to date against the industry's decline of 12%. While shares of BAX and OM have gained 2.8% and 4.3%, respectively, in the same period, those of DVA have lost 8.9%. The S&P 500 Index has increased 0.8% in the same time frame. YTD Performance Chart Image Source: Zacks Investment Research Fresenius Medical currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Outset Medical, Inc. (OM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
22-06-2025
- Business
- Yahoo
Are Poor Financial Prospects Dragging Down Fresenius Medical Care AG (ETR:FME Stock?
With its stock down 9.1% over the past month, it is easy to disregard Fresenius Medical Care (ETR:FME). We decided to study the company's financials to determine if the downtrend will continue as the long-term performance of a company usually dictates market outcomes. Particularly, we will be paying attention to Fresenius Medical Care's ROE today. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Fresenius Medical Care is: 5.2% = €812m ÷ €16b (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. So, this means that for every €1 of its shareholder's investments, the company generates a profit of €0.05. Check out our latest analysis for Fresenius Medical Care We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. When you first look at it, Fresenius Medical Care's ROE doesn't look that attractive. However, given that the company's ROE is similar to the average industry ROE of 5.1%, we may spare it some thought. But Fresenius Medical Care saw a five year net income decline of 21% over the past five years. Bear in mind, the company does have a slightly low ROE. Hence, this goes some way in explaining the shrinking earnings. However, when we compared Fresenius Medical Care's growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 16% in the same period. This is quite worrisome. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Fresenius Medical Care fairly valued compared to other companies? These 3 valuation measures might help you decide. With a high three-year median payout ratio of 55% (implying that 45% of the profits are retained), most of Fresenius Medical Care's profits are being paid to shareholders, which explains the company's shrinking earnings. With only a little being reinvested into the business, earnings growth would obviously be low or non-existent. Moreover, Fresenius Medical Care has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth. Upon studying the latest analysts' consensus data, we found that the company's future payout ratio is expected to drop to 39% over the next three years. As a result, the expected drop in Fresenius Medical Care's payout ratio explains the anticipated rise in the company's future ROE to 8.3%, over the same period. On the whole, Fresenius Medical Care's performance is quite a big let-down. Because the company is not reinvesting much into the business, and given the low ROE, it's not surprising to see the lack or absence of growth in its earnings. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
